Department of Nephrology, University Hospital Reina Sofia, Cordoba, Spain.
J Nephrol. 2013 Jan-Feb;26(1):119-28. doi: 10.5301/jn.5000116.
Geographical differences in disease prevalence and mortality have been described in the general population and in chronic kidney disease patients in Europe. In this secondary analysis of the Membrane Permeability Outcome (MPO) study, we addressed differences in patient and treatment patterns, and whether these affect patient outcomes.
Participating countries were grouped according to geographical location; thus study centers in France, Greece, Italy, Portugal and Spain were allocated to southern Europe (n=499), and those in all other countries (Belgium, Germany, Poland and Sweden) to northern Europe (n=148). Descriptive analysis of patient and treatment patterns at study start, as well as survival analysis, was performed.
In patients from the northern European countries, a higher prevalence of diabetes mellitus and of cardiovascular disease was observed than in those from southern Europe (diabetes 35.1% vs. 21.0%, p=0.0007; cardiovascular disease 40.5% vs. 22.8%, p<0.0001). In northern Europe, 23% of patients started hemodialysis with a catheter for vascular access, while in southern European centers, only 13% did so (p=0.0042). Kaplan-Meier survival analysis revealed a lower probability for both all-cause and cardiovascular mortality in southern Europe (log-rank test p<0.001). In a Cox proportional hazards model, a higher mortality risk was estimated for the northern European patients after adjustment for age, sex, membrane permeability, comorbidity index and vascular access (hazard ratio = 1.831; 95% confidence interval, 1.282-2.615; p=0.0009).
Our study patients from northern Europe showed a higher risk profile than those from southern Europe. However, only some of the factors can be modified in attempts to lower the mortality risk in this geographical area.
疾病的流行和死亡率在欧洲的普通人群和慢性肾脏病患者中已有地域差异的描述。在 MPO 研究的二次分析中,我们解决了患者和治疗模式的差异,以及这些差异是否会影响患者的结局。
根据地理位置将参与的国家分组;因此,法国、希腊、意大利、葡萄牙和西班牙的研究中心被分配到南欧(n=499),而所有其他国家(比利时、德国、波兰和瑞典)的研究中心被分配到北欧(n=148)。对研究开始时患者和治疗模式的描述性分析,以及生存分析。
在北欧国家的患者中,糖尿病和心血管疾病的患病率高于南欧(糖尿病 35.1%对 21.0%,p=0.0007;心血管疾病 40.5%对 22.8%,p<0.0001)。在北欧,23%的患者开始使用导管进行血液透析以建立血管通路,而在南欧中心,只有 13%的患者这样做(p=0.0042)。Kaplan-Meier 生存分析显示,南欧的全因和心血管死亡率的可能性较低(对数秩检验 p<0.001)。在 Cox 比例风险模型中,调整年龄、性别、膜通透性、合并症指数和血管通路后,北欧患者的死亡风险更高(风险比=1.831;95%置信区间,1.282-2.615;p=0.0009)。
我们的研究患者来自北欧,其风险状况高于南欧。然而,在试图降低该地理区域的死亡率风险时,只有部分因素可以改变。